GM Tops the List of “Most Exposed to China”
This year, GM swapped positions with Ford. GM is the most exposed to China while Ford has declined to No. 5.
CPA’s Jeff Ferry Teaches the Next Generation How to Rebuild American Industry
CPA’s chief economist emeritus, Jeff Ferry, has gone back to school in his semi-retirement years. This time, though, it was a speaking gig at the University of Florida’s new Semiconductor Institute in Gainesville.
CPA Economist Leads Rare Bipartisan Push to Fix America’s Generic Drug Crisis
CPA Economist Andrew Rechenberg gave his testimony and answered questions in a four- panelist hearing. It was arguably the most agreeable hearing in years. A bipartisan consensus on America’s generic drug supply chain is nearly fully formed now.
New CPA Economic Report on ‘The New Biotech Cold War’
Titled “The New Biotech Cold War: The U.S. Medicine Can’t Afford to Fall Behind China,” the report shows how U.S. biotech – long a pillar of national strength – no longer has a guaranteed edge globally.
Pharmaceutical 232 Must Cover Generic Drugs to Fulfill President’s Promise of Reshoring Essential Medicine Production
The Trump administration’s Section 232 investigation into pharmaceutical imports is reportedly close to being final. The final investigation’s success will depend largely on whether or not the Commerce Department determines that there is a crisis in the generics industry — an issue that President Trump highlighted back in 2023.
U.S. Businesses Across Industries Launch Alliance to Spotlight Trade Fraud and Demand Enforcement Outcomes
Strong enforcement against trade fraud isn’t optional—it’s essential to rebuilding our industrial base and securing long-term prosperity for American communities.
New CPA Economic Report Focuses on Growing Crisis for American Shipbuilding Industry
The U.S. Shipbuilding Base has Withered Since the 80s; Latest CPA Report Examines What’s Needed to Bring it Back
Tariffs Are Not Causing Inflation: Breaking Down August 2025 CPI
The August 2025 inflation report has reignited debate over tariffs. Some pundits have been quick to blame trade policy for rising prices, invoking Smoot-Hawley comparisons and warning of disaster on the scale of the Great Depression. But the data tells a different story.
CPA Applauds Launch of Robotics, Industrial Machinery, and Medical Device Section 232 Investigations
The latest Section 232 announcements expand the list of ongoing investigations into imported goods that could be exposed to higher tariffs.
China Now Producing Dozens of Drugs Below Market Price – Dumping Them Globally is Next Move
As proof that no company can match China on price, Chinese producers of active pharmaceutical ingredients (APIs) and the key starting materials (KSMs) used to make them are slashing prices by up to 50%. Not even low-cost India – one of the largest importers of Chinese KSMs – can compete at those levels.
